Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="135354.fig.002a" src="https://static-preview.hindawi.com/articles/jo/volume-2010/135354/figures/135354.fig.002a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>Microarray data on primary renal cell carcinoma samples</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="135354.fig.002b" src="https://static-preview.hindawi.com/articles/jo/volume-2010/135354/figures/135354.fig.002b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>Microarray data on primary sarcoma samples</td></tr></table></td></tr></table>

<table>Measurement of <i>MPL</i>, <i>EPOR</i>, <i>ERBB2</i>, and <i>IGF1R</i> mRNA in renal cell carcinoma and soft tissue and bony/cartilage sarcoma tumor samples using microarray analysis. Robust microarray average (RMA) was used for assay normalization. The levels of gene expression of <i>MPL</i>, <i>EPOR</i>, <i>ERBB2</i>, and <i>IGF1R</i> mRNA were reported as RMA intensity values.</table>

Journal of Oncology

fig2

Figure 2

Figure 2: Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors 